109 related articles for article (PubMed ID: 19214978)
1. Presentation of childhood CML mimicking bone sarcoma.
Radhakrishnan S; Das P; Singh S; Kalita D; Gupta SD; Bakhshi S
Pediatr Blood Cancer; 2009 Jul; 52(7):901-2. PubMed ID: 19214978
[No Abstract] [Full Text] [Related]
2. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
[No Abstract] [Full Text] [Related]
3. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
4. Survival more than 19 years after the diagnosis of accelerated phase of chronic myelocytic leukemia.
Wiernik PH; Baig MA; Lee SH; Dutcher JP; Paietta E; Racevskis J
Clin Adv Hematol Oncol; 2011 Mar; 9(3):242-8. PubMed ID: 21475132
[No Abstract] [Full Text] [Related]
5. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
Aftimos P; Nasr F
Leuk Res; 2009 Nov; 33(11):e178-80. PubMed ID: 19446330
[No Abstract] [Full Text] [Related]
6. A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.
Janssen JJ; Berendse HW; Schuurhuis GJ; Merle PA; Ossenkoppele GJ
Am J Hematol; 2009 Oct; 84(10):679-82. PubMed ID: 19658186
[No Abstract] [Full Text] [Related]
7. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
Strout MP; Schatz DG
Cancer Cell; 2009 Sep; 16(3):174-6. PubMed ID: 19732715
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia and gastrointestinal stromal tumor: simultaneous presentation.
Gollard R; Wierda W; Trent J
J Clin Oncol; 2007 Oct; 25(29):4682-3. PubMed ID: 17925564
[No Abstract] [Full Text] [Related]
9. Follow-up study of patients diagnosed with chronic myelogenous leukemia treated with STI 571 in Ecuador.
Paz-Y-Miño C; Arévalo M; Sánchez ME; Cañizares C; Leone PE
Arch Med Res; 2007 Apr; 38(3):364-5. PubMed ID: 17350491
[No Abstract] [Full Text] [Related]
10. Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
Ramamoorthy SK; Pandita R; Prakash A; Ramaswamy NV; Al Bahar S
Acta Haematol; 2007; 118(3):141-5. PubMed ID: 17804901
[TBL] [Abstract][Full Text] [Related]
11. [Chronic myeloid leukemia:specific characteristics and targeted therapy].
Nacinović-Duletić A
Lijec Vjesn; 2007 May; 129 Suppl 3():5-9. PubMed ID: 18972633
[No Abstract] [Full Text] [Related]
12. Persistence of molecular remission throughout pregnancy in CML after imatinib.
Sorà F; De Matteis S; Bajer J; D'alò F; Leone G; Sica S
Leuk Res; 2009 Jun; 33(6):e6-7. PubMed ID: 18937976
[No Abstract] [Full Text] [Related]
13. Biphenotypic extramedullary blast crisis as a presenting manifestation of Philadelphia chromosome-positive CML in a child.
Ganessan K; Goel R; Kumar K; Bakhshi S
Pediatr Hematol Oncol; 2007; 24(3):195-8. PubMed ID: 17454789
[TBL] [Abstract][Full Text] [Related]
14. Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia.
Uchiyama M; Ikeda T
Leuk Res; 2009 Dec; 33(12):1723-4. PubMed ID: 19580999
[No Abstract] [Full Text] [Related]
15. Bone marrow necrosis related to imatinib mesylate therapy for cml bilineal blast crisis.
Campiotti L; Codari R; Appio L; Ultori C; Solbiati F; Maria Grandi A; Venco A
Leuk Res; 2007 Dec; 31(12):1768-70. PubMed ID: 17403537
[No Abstract] [Full Text] [Related]
16. Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia.
Jin J; Chen H; Cao L
Leuk Res; 2009 Jun; 33(6):e18-9. PubMed ID: 19108890
[No Abstract] [Full Text] [Related]
17. Recurrence of lymphoid blast crisis over 20 years after successful sibling allo-SCT for CML: short lived complete cytogenetic response to imatinib.
Irvine DA; Shepherd JD
Bone Marrow Transplant; 2009 Aug; 44(4):267-8. PubMed ID: 19234506
[No Abstract] [Full Text] [Related]
18. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
19. Hypolipemiant besides antileukemic effect of imatinib mesylate.
Gologan R; Constantinescu G; Georgescu D; Ostroveanu D; Vasilache D; Dobrea C; Iancu D; Popov V
Leuk Res; 2009 Sep; 33(9):1285-7. PubMed ID: 19327828
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.
Ditschkowski M; Haferlach C; Schulte C; Trenschel R; Beelen DW
Bone Marrow Transplant; 2009 Aug; 44(4):265-6. PubMed ID: 19234516
[No Abstract] [Full Text] [Related]
[Next] [New Search]
